Urgent 2024 AI Prediction By Legend Who Picked Samsara, Gitlab & Crowdstrike

Stocks shoot higher for the next 5 to 10 years....................................................................................

Unsubscribe Dear Reader,   Don't let it happen again.   In 2023, we saw certain A.I investments like: C3.ai and Upstart Holdings soar by 159% and 217%, respectively…   We saw the path to A.I. riches with some incredible overnight gains for companies that use AI. Gains like, 345%... 511%... and 3,100%!   And while those stories are in the rear view mirror…   Legendary tech investor, Alex Green, is bringing an important announcement for any Main Street investor looking to profit big from AI in 2024.   He claims:   Starting today, YOU have a SECOND CHANCE to for A.I. riches   Because a brand new "Phase 2" in AI development will open the window for an even larger, faster, investment opportunity…   One that is set to deliver gains many times BIGGER than the incredible results we have already seen in AI.   How many times bigger?   Barron's says this AI development can grow the U.S. economy by a whopping 10,000%.   Investment bank, UBS Group published: "We upgrade our AI revenue forecasts to 15x growth between 2022 and 2027."   Top investor Paul Tudor Jones predicts we will see: "Stocks shoot higher for the next 5 to 10 years… With huge individual winners up [for the taking.]"   And if you make just one move with your money today…   One move which Alex Green himself will detail for FREE in this special presentation…   You can potentially grab one of these winners to begin amassing your tidy fortune.   Click here now for his FREE urgent briefing.   Good investing,    Alexander Green Chief Investment Strategist, The Oxford Club This ad is sent on behalf of The Oxford Club, 105 W. Monument Street Baltimore, MD 21201. If you would like to opt out from receiving offers from The Oxford Club, please click here This is a PAID ADVERTISEMENT provided to the subscribers of StockEarnings Free Newsletter. Although we have sent you this email, StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above. Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe . StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com

Urgent 2024 AI Prediction By Legend Who Picked Samsara, Gitlab & Crowdstrike

Stocks shoot higher for the next 5 to 10 years....................................................................................

Unsubscribe Dear Reader,   Don't let it happen again.   In 2023, we saw certain A.I investments like: C3.ai and Upstart Holdings soar by 159% and 217%, respectively…   We saw the path to A.I. riches with some incredible overnight gains for companies that use AI. Gains like, 345%... 511%... and 3,100%!   And while those stories are in the rear view mirror…   Legendary tech investor, Alex Green, is bringing an important announcement for any Main Street investor looking to profit big from AI in 2024.   He claims:   Starting today, YOU have a SECOND CHANCE to for A.I. riches   Because a brand new "Phase 2" in AI development will open the window for an even larger, faster, investment opportunity…   One that is set to deliver gains many times BIGGER than the incredible results we have already seen in AI.   How many times bigger?   Barron's says this AI development can grow the U.S. economy by a whopping 10,000%.   Investment bank, UBS Group published: "We upgrade our AI revenue forecasts to 15x growth between 2022 and 2027."   Top investor Paul Tudor Jones predicts we will see: "Stocks shoot higher for the next 5 to 10 years… With huge individual winners up [for the taking.]"   And if you make just one move with your money today…   One move which Alex Green himself will detail for FREE in this special presentation…   You can potentially grab one of these winners to begin amassing your tidy fortune.   Click here now for his FREE urgent briefing.   Good investing,    Alexander Green Chief Investment Strategist, The Oxford Club This ad is sent on behalf of The Oxford Club, 105 W. Monument Street Baltimore, MD 21201. If you would like to opt out from receiving offers from The Oxford Club, please click here This is a PAID ADVERTISEMENT provided to the subscribers of StockEarnings Free Newsletter. Although we have sent you this email, StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above. Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe . StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com

Urgent 2024 AI Prediction By Legend Who Picked Samsara, Gitlab & Crowdstrike

Stocks shoot higher for the next 5 to 10 years....................................................................................

Unsubscribe Dear Reader,   Don't let it happen again.   In 2023, we saw certain A.I investments like: C3.ai and Upstart Holdings soar by 159% and 217%, respectively…   We saw the path to A.I. riches with some incredible overnight gains for companies that use AI. Gains like, 345%... 511%... and 3,100%!   And while those stories are in the rear view mirror…   Legendary tech investor, Alex Green, is bringing an important announcement for any Main Street investor looking to profit big from AI in 2024.   He claims:   Starting today, YOU have a SECOND CHANCE to for A.I. riches   Because a brand new "Phase 2" in AI development will open the window for an even larger, faster, investment opportunity…   One that is set to deliver gains many times BIGGER than the incredible results we have already seen in AI.   How many times bigger?   Barron's says this AI development can grow the U.S. economy by a whopping 10,000%.   Investment bank, UBS Group published: "We upgrade our AI revenue forecasts to 15x growth between 2022 and 2027."   Top investor Paul Tudor Jones predicts we will see: "Stocks shoot higher for the next 5 to 10 years… With huge individual winners up [for the taking.]"   And if you make just one move with your money today…   One move which Alex Green himself will detail for FREE in this special presentation…   You can potentially grab one of these winners to begin amassing your tidy fortune.   Click here now for his FREE urgent briefing.   Good investing,    Alexander Green Chief Investment Strategist, The Oxford Club This ad is sent on behalf of The Oxford Club, 105 W. Monument Street Baltimore, MD 21201. If you would like to opt out from receiving offers from The Oxford Club, please click here This is a PAID ADVERTISEMENT provided to the subscribers of StockEarnings Free Newsletter. Although we have sent you this email, StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above. Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe . StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com

One Great Coin (is all it takes)...

10x... 50x... even 150x ....................................................................................

Unsubscribe Dear reader, It's true — sometimes all it takes is getting in on one great coin at the right time. And with my #1 coin for February 2024… you could have the potential to bank 10x… 50x… and even 150x.. In the coming bull run. Because right now – it's the perfect storm of once-in-a-lifetime opportunities converging with this one coin. But here's the thing… And it's important that you're aware… Your window to get in EARLY on this coin is about to close. Don't miss your chance… all the details are on the next page. Talk soon, Bryce Paul Crypto 101 P.S. I truly believe this crypto could be one of the top earning cryptos of all time. Don't miss out >>> Take a look © 2024 Boardwalk Flock LLC. All Rights Reserved. 1596 N Coast Highway 101 #1037 Encinitas, CA 92024 The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Readers acknowledge that the authors are not engaging in the rendering of legal, financial, medical, or professional advice. The reader agrees that under no circumstances Boardwalk Flock, LLC is responsible for any losses, direct or indirect, which are incurred as a result of the use of the information contained within this, including, but not limited to, errors, omissions, or inaccuracies. Results may not be typical and may vary from person to person. Making money trading digital currencies takes time and hard work. There are inherent risks involved with investing, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. This is a PAID ADVERTISEMENT provided to the subscribers of StockEarnings Free Newsletter. Although we have sent you this email, StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above. Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe . StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com

Breaking News: Some Jan. 6 sentences were improperly lengthened, appeals court rules

Breaking News Alert

Some Jan. 6 sentences were improperly lengthened, appeals court rules 03/01/2024 12:05 PM EST The decision could force trial judges to recalculate sentences for Jan. 6 rioters who were convicted of obstruction. Read the latest

You received this email because you are subscribed to POLITICO's Breaking News Alerts. Download the mobile app for iOS or Android | Manage your alert settings | Unsubscribe Privacy Policy  |  Terms of Service POLITICO, LLC, 1000 Wilson Blvd. Arlington, VA 22209, USA

Urgent 2024 AI Prediction By Legend Who Picked Samsara, Gitlab & Crowdstrike

Stocks shoot higher for the next 5 to 10 years....................................................................................

Unsubscribe Dear Reader,   Don't let it happen again.   In 2023, we saw certain A.I investments like: C3.ai and Upstart Holdings soar by 159% and 217%, respectively…   We saw the path to A.I. riches with some incredible overnight gains for companies that use AI. Gains like, 345%... 511%... and 3,100%!   And while those stories are in the rear view mirror…   Legendary tech investor, Alex Green, is bringing an important announcement for any Main Street investor looking to profit big from AI in 2024.   He claims:   Starting today, YOU have a SECOND CHANCE to for A.I. riches   Because a brand new "Phase 2" in AI development will open the window for an even larger, faster, investment opportunity…   One that is set to deliver gains many times BIGGER than the incredible results we have already seen in AI.   How many times bigger?   Barron's says this AI development can grow the U.S. economy by a whopping 10,000%.   Investment bank, UBS Group published: "We upgrade our AI revenue forecasts to 15x growth between 2022 and 2027."   Top investor Paul Tudor Jones predicts we will see: "Stocks shoot higher for the next 5 to 10 years… With huge individual winners up [for the taking.]"   And if you make just one move with your money today…   One move which Alex Green himself will detail for FREE in this special presentation…   You can potentially grab one of these winners to begin amassing your tidy fortune.   Click here now for his FREE urgent briefing.   Good investing,    Alexander Green Chief Investment Strategist, The Oxford Club This ad is sent on behalf of The Oxford Club, 105 W. Monument Street Baltimore, MD 21201. If you would like to opt out from receiving offers from The Oxford Club, please click here This is a PAID ADVERTISEMENT provided to the subscribers of StockEarnings Free Newsletter. Although we have sent you this email, StockEarnings does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above. Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe . StockEarnings, Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA W: 877.6.STOCKS StockEarnings.com

Dems blast bills to reopen IRA

Delivered every Tuesday and Friday by 12 p.m., Prescription Pulse examines the latest pharmaceutical news and policy.

Mar 01, 2024 View in browser   By Lauren Gardner and David Lim Driving The Day Rep. Frank Pallone opposes new legislation involving drugs for rare diseases, saying the bills would hinder innovation and patient access. | Francis Chung/POLITICO E&C DEMS PAN ‘RARE’ IRA CHANGES — Two senior House Energy and Commerce Democrats said Thursday they oppose three bipartisan bills that would broaden rare-disease drug safe harbors from Medicare’s new price negotiation program. The resistance from the panel’s top Democrat, Rep. Frank Pallone of New Jersey, and the health subcommittee’s ranking member, Rep. Anna Eshoo (D-Calif.), likely dooms what would have been a long-shot effort in an election year — with Democrats controlling the Senate and the White House — to tweak portions of the Inflation Reduction Act , President Joe Biden’s signature legislative achievement. It also came on Rare Disease Day, which falls on the last day of February. “Medicare drug price negotiation is only focused on the top-selling, high-cost Medicare drugs without any market competition,” Eshoo said at a hearing on 18 bills, most of which are focused on rare disease issues. “The bills before us today attempt to create unneeded loopholes to chip away at Medicare’s power to negotiate and will raise costs for beneficiaries and taxpayers.” The bills in question: One measure would expand the program exemption for so-called orphan drugs — FDA-designated products for rare conditions that qualify for certain pre- and post-approval benefits to encourage development — to include drugs treating multiple rare diseases. Another bill would keep certain gene therapies out of the program for 11 years after their debut. And a third would phase in plasma-based medicines to the manufacturer discount program. Is past prologue? Big legislative packages are often amended in later years once lawmakers realize unintended consequences or outright errors passed into a statute. Rep. Wiley Nickel (D-N.C.), who co-sponsored all three IRA-related bills, suggested in December that, since the Affordable Care Act was “refined” over the years since its 2010 passage, the same was likely for the IRA. But Pallone made it clear he thinks the law’s existing orphan drug exclusion, which shields products treating a single rare disease from negotiations, is sufficient to protect innovation while saving beneficiaries money. “I don’t know what the point is in having a drug if you can’t buy it and you can’t use it,” he said. On other bills: Pallone signaled hesitation about advancing several other bipartisan bills considered Thursday that would require FDA resources to implement without hearing first from the agency. That includes a bill co-sponsored by Eschoo to reauthorize the FDA’s priority review voucher program for rare pediatric diseases. IT’S FRIDAY. WELCOME BACK TO PRESCRIPTION PULSE. Is anyone else already getting started on their allergy medicine this year? Send news and tips to Lauren Gardner (lgardner@politico.com or @Gardner_LM) or David Lim (dlim@politico.com or @davidalim). Eye on the FDA FDA Commissioner Robert Califf is under fire from pharmacy compounders over remarks he made about compounded weight-loss drugs. | Manuel Balce Ceneta/AP HITTING BACK AGAINST CALIFF — The trade association for pharmacy compounders urged FDA Commissioner Robert Califf to walk back comments he made this week that the group says conflates legitimately compounded weight-loss drugs with counterfeit versions. What Califf said: “People are attracted to compounded versions of this without the requisite controls to make sure that what you’re buying is actually the active drug and not something that’s contaminated or not even the active drug at all,” Califf said, noting ongoing shortages of brand-name options by drugmakers Eli Lilly and Novo Nordisk. “We could use more authority in the area of compounding and control of illicit markets that happen on the internet,” he later added. “That’s a very difficult area.” Compounders respond: Alliance for Pharmacy Compounding CEO Scott Brunner said the direct-to-consumer sale of any substance advertised as an FDA-approved drug without a prescription is illegal. Califf’s comments, Brunner added, could spur patients to question the safety and legitimacy of compounded drugs prescribed to them. “APC strongly supports FDA’s efforts to end the sale of illicit substances, which put consumers at risk,” he said in a statement. “At the same time, we urge the agency to take care in enunciating the difference between actual counterfeit products and legitimate compounded drugs.”   CONGRESS OVERDRIVE: Since day one, POLITICO has been laser-focused on Capitol Hill, serving up the juiciest Congress coverage. Now, we’re upping our game to ensure you’re up to speed and in the know on every tasty morsel and newsy nugget from inside the Capitol Dome, around the clock. Wake up, read Playbook AM, get up to speed at midday with our Playbook PM halftime report, and fuel your nightly conversations with Inside Congress in the evening. Plus, never miss a beat with buzzy, real-time updates throughout the day via our Inside Congress Live feature. Learn more and subscribe here.     Coronavirus SPRING (BOOST) AHEAD — The CDC endorsed its outside expert panel’s recommendation Wednesday that adults 65 and older should receive an additional Covid-19 shot with the current formulation. The agency’s Covid working group had proposed a less stringent recommendation that those individuals “may” get another dose, but some advisers worried that would foment confusion among patients and providers about the vaccine’s benefits. Still, CDC and FDA officials noted that the greater public health benefit would come from convincing the 60 percent of older adults who haven’t gotten a first dose of the updated vaccine to roll up their sleeves. Drug Pricing DEAL OR NO DEAL? Drugmakers selected for the first Medicare drug price negotiations have until March 2 to decide whether to accept CMS’ initial price offer or put forward a counteroffer. If CMS does not accept each company’s price counteroffer, the two sides will meet up to three times to negotiate a maximum fair price for the selected drugs that will kick into effect in 2026 — but the details of the talks will not be made public unless disclosed by drugmakers. “CMS will not publicly discuss ongoing negotiations with a participating drug company, except if a participating drug company discloses information about the negotiations that is made public prior to CMS releasing an explanation of the negotiated price,” CMS said in an emailed statement. One drugmaker, Novartis, said it does not plan to say whether it will give a counteroffer to CMS. “We don’t have plans to share this,” said Novartis spokesperson Michael Meo. What’s next: The negotiation window for the first set of drugs ends on Aug. 1. CMS is required to release an explanation of the final prices no later than March 1, 2025. In Congress ANOTHER CONTINUING RESOLUTION — The House agreed on another stopgap spending bill Thursday afternoon, which kicks funding deadlines for the government until March 8 for six bills, including one that funds the FDA, and March 22 for the other six. The Senate cleared the bill Thursday night for President Joe Biden’s signature. Pharma Worldwide ANOTHER PANDEMIC DEAL ROADBLOCK — Developing countries rejected a pathogen data-sharing proposal at the World Health Organization this week, POLITICO’s Rory O’Neill reports, dashing hopes for a breakthrough in negotiations over a new pandemic deal. A bloc of Global South countries considered the proposed agreement on benefit sharing too vague. It would have directed manufacturers — at the WHO’s request — to supply 10 percent of vaccines, drugs and diagnostic tools for free and another 10 percent at nonprofit prices during a crisis, with the allocations tied to legally binding contracts. CANADA UNVEILS DRUG PLAN — The Canadian government released a proposal Thursday to establish a national, single-payer system for prescription drug coverage. The legislation is billed as the program’s first phase, which would initially cover contraception and diabetes drugs. Document Drawer CMS published final guidance on Thursday for the Inflation Reduction Act’s Medicare Prescription Payment Plan.   YOUR TICKET INSIDE THE GOLDEN STATE POLITICAL ARENA: California Playbook delivers the latest intel, buzzy scoops and exclusive coverage from Sacramento and Los Angeles to Silicon Valley and across the state. Don't miss out on the daily must-read for political aficionados and professionals with an outsized interest in California politics, policy and power. Subscribe today.       Follow us on Twitter David Lim @davidalim Lauren Gardner @Gardner_LM   Follow us

To change your alert settings, please log in at https://login.politico.com/?redirect=https%3A%2F%2Fwww.politico.com/settings This email was sent to edwardlorilla1986.paxforex@blogger.com by: POLITICO, LLC 1000 Wilson Blvd. Arlington, VA, 22209, USA Unsubscribe | Privacy Policy | Terms of Service

Everyone loves an underdog…

But you know what's better?

Everyone loves an underdog…  But you know what's better than that?  An undefeated champion!  Gearing up for what could be its next big win!  Well folks…  That's exactly what my “2-Step Trade” has been doing for the past 12 months. Winning, winning, and winning some more.  And with AVGO heading into earnings - the stock is paying DOUBLE the premium!  And while I can never promise future returns or against losses, the stars are aligning and there couldn't be a better time to share this strategy with you.  So if you want in on what could be the 17th win in a row - RSVP for Monday's event here.  Trade well,  Jack Carter  Disclaimer: The profits and performance shown are not typical to any individual subscriber to the service, we make no future earnings claims, and you may lose money. From 01/08/21 through 02/23/24, the average win rate is 97%, the average return per position is 3.20% with an average hold time of 4 days.

Everyone loves an underdog…    But you know what's better than that?    An undefeated champion!    Gearing up for what could be its next big win!    Well folks…    That's exactly what my “2-Step Trade” has been doing for the past 12 months.   Winning, winning, and winning some more.    And with AVGO heading into earnings - the stock is paying DOUBLE the premium!    And while I can never promise future returns or against losses, the stars are aligning and there couldn't be a better time to share this strategy with you.    So if you want in on what could be the 17th win in a row - RSVP for Monday's event here.    Trade well,  Jack Carter    Disclaimer: The profits and performance shown are not typical to any individual subscriber to the service, we make no future earnings claims, and you may lose money. From 01/08/21 through 02/23/24, the average win rate is 97%, the average return per position is 3.20% with an average hold time of 4 days.

ABOUT US:  We believe that the opportunity for financial literacy and freedom belongs to all people, not just those who already have years of investing experience. Prosperity Pub provides an array of educational services and products that will help you navigate the markets and become a better investor. Trading is made simple through our online forum full of trading techniques to give you the best tools to kick-start your investing journey. We offer collaborative webinars and training; we love to teach. No matter the opportunity, we bring together a strong community of like-minded traders to focus on analyzing market news as it’s presented each day. DISCLAIMER: FOR INFORMATION PURPOSES ONLY. The materials presented from Prosperity Pub are for your informational purposes only. Neither Prosperity Pub nor its employees offer investment, legal or tax advice of any kind, and the analysis displayed with various tools does not constitute investment, legal or tax advice and should not be interpreted as such. Using the data and analysis contained in the materials for reasons other than the informational purposes intended is at the user’s own risk. DISCLAIMER: TRADE AT YOUR OWN RISK; TRADING INVOLVES RISK OF LOSS; SEEK PROFESSIONAL ADVICE. Prosperity Pub is not responsible for any losses that may occur from transactions effected based upon information or analysis contained in the presented. To the extent that you make use of the concepts with the presentation material, you are solely responsible for the applicable trading or investment decision. Trading activity, including options transactions, can involve the risk of loss, so use caution when entering any option transaction. You trade at your own risk, and it is recommended you consult with a financial advisor for investment, legal or tax advice relating to options transactions.  Please visit https://prosperitypub.com/terms-conditions/ for our full Terms and Conditions. Unsubscribe This email was sent to edwardlorilla1986.paxforex@blogger.com by Prosperity Pub 101 Marketside Ave, Suite 404 PMB 318, Ponte Vedra, Florida 32081, United States Prosperity Pub

ABOUT US:  We believe that the opportunity for financial literacy and freedom belongs to all people, not just those who already have years of investing experience. Prosperity Pub provides an array of educational services and products that will help you navigate the markets and become a better investor. Trading is made simple through our online forum full of trading techniques to give you the best tools to kick-start your investing journey. We offer collaborative webinars and training; we love to teach. No matter the opportunity, we bring together a strong community of like-minded traders to focus on analyzing market news as it’s presented each day. DISCLAIMER: FOR INFORMATION PURPOSES ONLY. The materials presented from Prosperity Pub are for your informational purposes only. Neither Prosperity Pub nor its employees offer investment, legal or tax advice of any kind, and the analysis displayed with various tools does not constitute investment, legal or tax advice and should not be interpreted as such. Using the data and analysis contained in the materials for reasons other than the informational purposes intended is at the user’s own risk. DISCLAIMER: TRADE AT YOUR OWN RISK; TRADING INVOLVES RISK OF LOSS; SEEK PROFESSIONAL ADVICE. Prosperity Pub is not responsible for any losses that may occur from transactions effected based upon information or analysis contained in the presented. To the extent that you make use of the concepts with the presentation material, you are solely responsible for the applicable trading or investment decision. Trading activity, including options transactions, can involve the risk of loss, so use caution when entering any option transaction. You trade at your own risk, and it is recommended you consult with a financial advisor for investment, legal or tax advice relating to options transactions.  Please visit https://prosperitypub.com/terms-conditions/ for our full Terms and Conditions. Unsubscribe This email was sent to edwardlorilla1986.paxforex@blogger.com by Prosperity Pub 101 Marketside Ave, Suite 404 PMB 318, Ponte Vedra, Florida 32081, United States Prosperity Pub